Cervical cancer, Secondary cancers
Open
Phase 3
This study is looking at sacituzumab tirumotecan for cervical cancer that has spread to another part of the body or has come back during or after treatment. This is called advanced cervical cancer.
It is for people with advanced cervical cancer who cannot have surgery or radiotherapy with the aim to cure.
Sacituzumab tirumotecan is also called sac-TMT and MK-2870.
You pronounce sacituzumab tirumotecan as sass-ih-too-zo-mab tie-rum-o-tee-can.
Recruitment start: 18 June 2026
Recruitment end: 23 March 2028
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Lisa Barraclough
Merck Sharp & Dohme Ltd
Last reviewed: 07 Aug 2026
CRUK internal database number: 20160